FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311582377> ?p ?o ?g. }

• W4311582377 endingPage "1781" @default.
• W4311582377 startingPage "1768" @default.
• W4311582377 abstract "The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia (AML) in patients not benefiting from intensive chemotherapy. Nevertheless, treatment failure remains a challenge, and predictive markers are needed, particularly for relapsed or refractory AML. Ex vivo drug sensitivity testing may correlate with outcomes, but its prospective predictive value remains unexplored. Here we report the results of the first stage of the prospective phase II VenEx trial evaluating the utility and predictiveness of venetoclax sensitivity testing using different cell culture conditions and cell viability assays in patients receiving venetoclax-azacitidine. Participants with de novo AML ineligible for intensive chemotherapy, relapsed or refractory AML, or secondary AML were included. The primary endpoint was the treatment response in participants showing ex vivo sensitivity and the key secondary endpoints were the correlation of sensitivity with responses and survival. Venetoclax sensitivity testing was successful in 38/39 participants. Experimental conditions significantly influenced the predictive accuracy. Blast-specific venetoclax sensitivity measured in conditioned medium most accurately correlated with treatment outcomes; 88% of sensitive participants achieved a treatment response. The median survival was significantly longer for participants who were ex vivo-sensitive to venetoclax (14.6 months for venetoclax-sensitive patients vs. 3.5 for venetoclax-insensitive patients, P<0.001). This analysis illustrates the feasibility of integrating drug-response profiling into clinical practice and demonstrates excellent predictivity. This trial is registered with ClinicalTrials.gov identifier: NCT04267081." @default.
• W4311582377 created "2022-12-27" @default.
• W4311582377 creator A5003328017 @default.
• W4311582377 creator A5008290909 @default.
• W4311582377 creator A5008625125 @default.
• W4311582377 creator A5014441735 @default.
• W4311582377 creator A5017560855 @default.
• W4311582377 creator A5019743697 @default.
• W4311582377 creator A5021708697 @default.
• W4311582377 creator A5028974486 @default.
• W4311582377 creator A5031608512 @default.
• W4311582377 creator A5035197183 @default.
• W4311582377 creator A5040796609 @default.
• W4311582377 creator A5042060760 @default.
• W4311582377 creator A5047154150 @default.
• W4311582377 creator A5050763201 @default.
• W4311582377 creator A5050873337 @default.
• W4311582377 creator A5058714222 @default.
• W4311582377 creator A5060191181 @default.
• W4311582377 creator A5061588223 @default.
• W4311582377 creator A5061939140 @default.
• W4311582377 creator A5064764393 @default.
• W4311582377 creator A5067760174 @default.
• W4311582377 creator A5070175326 @default.
• W4311582377 creator A5079013272 @default.
• W4311582377 creator A5091376212 @default.
• W4311582377 creator A5091454366 @default.
• W4311582377 date "2022-12-15" @default.
• W4311582377 modified "2023-10-17" @default.
• W4311582377 title "<i>Ex vivo</i> venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia" @default.
• W4311582377 cites W1964044574 @default.
• W4311582377 cites W1999922837 @default.
• W4311582377 cites W2002783575 @default.
• W4311582377 cites W2017580965 @default.
• W4311582377 cites W2018326038 @default.
• W4311582377 cites W2470668351 @default.
• W4311582377 cites W2559537906 @default.
• W4311582377 cites W2769605488 @default.
• W4311582377 cites W2896480326 @default.
• W4311582377 cites W2901513907 @default.
• W4311582377 cites W2909129451 @default.
• W4311582377 cites W2949007626 @default.
• W4311582377 cites W2956213465 @default.
• W4311582377 cites W2966720582 @default.
• W4311582377 cites W2999850201 @default.
• W4311582377 cites W3000515035 @default.
• W4311582377 cites W3001120382 @default.
• W4311582377 cites W3036598834 @default.
• W4311582377 cites W3048827006 @default.
• W4311582377 cites W3069119239 @default.
• W4311582377 cites W3083003645 @default.
• W4311582377 cites W3098856610 @default.
• W4311582377 cites W3135596931 @default.
• W4311582377 cites W3202266999 @default.
• W4311582377 cites W3205761999 @default.
• W4311582377 cites W3214427435 @default.
• W4311582377 cites W4200579603 @default.
• W4311582377 cites W4293253462 @default.
• W4311582377 cites W4379779275 @default.
• W4311582377 doi "https://doi.org/10.3324/haematol.2022.281692" @default.
• W4311582377 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36519325" @default.
• W4311582377 hasPublicationYear "2022" @default.
• W4311582377 type Work @default.
• W4311582377 citedByCount "4" @default.
• W4311582377 countsByYear W43115823772023 @default.
• W4311582377 crossrefType "journal-article" @default.
• W4311582377 hasAuthorship W4311582377A5003328017 @default.
• W4311582377 hasAuthorship W4311582377A5008290909 @default.
• W4311582377 hasAuthorship W4311582377A5008625125 @default.
• W4311582377 hasAuthorship W4311582377A5014441735 @default.
• W4311582377 hasAuthorship W4311582377A5017560855 @default.
• W4311582377 hasAuthorship W4311582377A5019743697 @default.
• W4311582377 hasAuthorship W4311582377A5021708697 @default.
• W4311582377 hasAuthorship W4311582377A5028974486 @default.
• W4311582377 hasAuthorship W4311582377A5031608512 @default.
• W4311582377 hasAuthorship W4311582377A5035197183 @default.
• W4311582377 hasAuthorship W4311582377A5040796609 @default.
• W4311582377 hasAuthorship W4311582377A5042060760 @default.
• W4311582377 hasAuthorship W4311582377A5047154150 @default.
• W4311582377 hasAuthorship W4311582377A5050763201 @default.
• W4311582377 hasAuthorship W4311582377A5050873337 @default.
• W4311582377 hasAuthorship W4311582377A5058714222 @default.
• W4311582377 hasAuthorship W4311582377A5060191181 @default.
• W4311582377 hasAuthorship W4311582377A5061588223 @default.
• W4311582377 hasAuthorship W4311582377A5061939140 @default.
• W4311582377 hasAuthorship W4311582377A5064764393 @default.
• W4311582377 hasAuthorship W4311582377A5067760174 @default.
• W4311582377 hasAuthorship W4311582377A5070175326 @default.
• W4311582377 hasAuthorship W4311582377A5079013272 @default.
• W4311582377 hasAuthorship W4311582377A5091376212 @default.
• W4311582377 hasAuthorship W4311582377A5091454366 @default.
• W4311582377 hasBestOaLocation W43115823771 @default.
• W4311582377 hasConcept C104317684 @default.
• W4311582377 hasConcept C126322002 @default.
• W4311582377 hasConcept C143998085 @default.
• W4311582377 hasConcept C150194340 @default.
• W4311582377 hasConcept C150903083 @default.
• W4311582377 hasConcept C190727270 @default.

• next